NEOT Neothetics, Inc.

1.97
+0  (7%)
Previous Close 1.84
Open 1.87
Price To book 2.13
Market Cap 27.23M
Shares 13,829,000
Volume 118,642
Short Ratio 2.37
Av. Daily Volume 314,347

SEC filingsSee all SEC filings

  1. 8-K - Current report 17733151
  2. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17708201
  3. 8-K - Current report 17708186
  4. 8-K - Current report 17672354
  5. 8-K - Current report 17609634

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 endpoints not met December 2015. Phase 2 trial initiated December 23, 2016 with data due June 2017.
LIPO-202
Reduction of localized fat deposits under the chin (submental fat)
Phase 2 trial planned pending data from submental trial.
LIPO-202
Reduction of central abdominal bulging

SEC Filings

  1. 8-K - Current report 17733151
  2. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17708201
  3. 8-K - Current report 17708186
  4. 8-K - Current report 17672354
  5. 8-K - Current report 17609634
  6. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17582546
  7. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17515095
  8. 10-Q - Quarterly report (Sections 13 or 15(d)) 161986057
  9. 8-K - Current report 161986042
  10. 8-K - Current report 161900191